1-5 of 5
Zhenyi Xue
Close
Sort by
Journal Articles

A Real-World Evaluation of Risk Factors for Disease Progression in Patients with Polycythemia Vera (PV) Enrolled in REVEAL

Michael R. Grunwald, Jeffrey I. Zwicker, Aaron T. Gerds, John M. Burke, Zhenyi Xue, Erin L. Crowgey, Justine Carl, Patricia Feldman, Evan M. Braunstein, Stephen Oh
Journal: Blood
Blood (2023) 142 (Supplement 1): 385.
https://doi.org/10.1182/blood-2023-180215
Published: 2023
Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa
Journal: Blood
Blood (2022) 140 (Supplement 1): 6810–6812.
https://doi.org/10.1182/blood-2022-158144
Published: 2022
Journal Articles

Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Anthea Peters, Grzegorz S. Nowakowski, Rosy Dabas, Theresa Amoloja, Zhenyi Xue, Caroline Koch, Eva E. Waltl, Isabelle Fleury
Journal: Blood
Blood (2022) 140 (Supplement 1): 3811–3813.
https://doi.org/10.1182/blood-2022-158550
Published: 2022
Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Robert Zeiser, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli
Journal: Blood
Blood (2022) 140 (Supplement 1): 10507–10508.
https://doi.org/10.1182/blood-2022-170186
Published: 2022
Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study

Gérard Socié, Zhenyi Xue, Valkal Bhatt, John Galvin, Mohamad Mohty
Journal: Blood
Blood (2022) 140 (Supplement 1): 4765–4766.
https://doi.org/10.1182/blood-2022-169717
Published: 2022